The impact of Cysteine-Rich Intestinal Protein 1 (CRIP1) in human breast cancer

Ludyga, Natalie; Englert, Sonja; Pflieger, Kerstin; Rauser, Sandra; Braselmann, Herbert; Walch, Axel; Auer, Gert; Höfler, Heinz; Aubele, Michaela
June 2013
Molecular Cancer;2013, Vol. 12 Issue 1, p1
Academic Journal
Background: CRIP1 (cysteine-rich intestinal protein 1) has been found in several tumor types, its prognostic impact and its role in cellular processes, particularly in breast cancer, are still unclear. Methods: To elucidate the prognostic impact of CRIP1, we analyzed tissues from 113 primary invasive ductal breast carcinomas using immunohistochemistry. For the functional characterization of CRIP1, its endogenous expression was transiently downregulated in T47D and BT474 breast cancer cells and the effects analyzed by immunoblotting, WST-1 proliferation assay and invasion assay. Results: We found a significant correlation between CRIP1 and HER2 (human epidermal growth factor receptor 2) expression levels (p = 0.016) in tumor tissues. In Kaplan Meier analyses, CRIP1 expression was significantly associated with the distant metastases-free survival of patients, revealing a better prognosis for high CRIP1 expression (p = 0.039). Moreover, in multivariate survival analyses, the expression of CRIP1 was an independent negative prognostic factor, along with the positive prognosticators nodal status and tumor size (p = 0.029). CRIP1 knockdown in the T47D and BT474 breast cancer cell lines led to the increased phosphorylation of MAPK and Akt, to the reduced phosphorylation of cdc2, and to a significantly elevated cell proliferation in vitro (p < 0.001). These results indicate that reduced CRIP1 levels may increase cell proliferation and activate cell growth. In addition, CRIP1 knockdown increased cell invasion in vitro. Conclusions: Because the lack of CRIP1 expression in breast cancer tissue is significantly associated with a worse prognosis for patients and low endogenous CRIP1 levels in vitro increased the malignant potential of breast cancer cells, we hypothesize that CRIP1 may act as a tumor suppressor in proliferation and invasion processes. Therefore, CRIP1 may be an independent prognostic marker with significant predictive power for use in breast cancer therapy.


Related Articles

  • Expression and prognostic value of Ars2 in hepatocellular carcinoma. He, Qian; Huang, Yongde; Cai, Lei; Zhang, Shaobo; Zhang, Chenghua // International Journal of Clinical Oncology;Oct2014, Vol. 19 Issue 5, p880 

    Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Arsenic resistance protein 2 (Asr2) was reported to be important for microRNA (miR) biogenesis, and its depletion could reduce the levels of several miRs, including miR-21, which is over-expressed in...

  • Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients. Krawczyk, Natalia; Hartkopf, Andreas; Banys, Malgorzata; Meier-Stiegen, Franziska; Staebler, Annette; Wallwiener, Markus; Röhm, Carmen; Hoffmann, Juergen; Hahn, Markus; Fehm, Tanja // BMC Cancer;2014, Vol. 14 Issue 1, p1201 

    Background An imbalance between cell proliferation and programmed cell death can result in tumor growth. Although most systemic cytotoxic agents induce apoptosis in tumor cells, a high apoptotic rate in primary breast cancer correlates with poor prognosis. The aim of this study was to...

  • Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters. Melling, Nathaniel; Thomsen, Erik; Tsourlakis, Maria Christina; Kluth, Martina; Hube-Magg, Claudia; Minner, Sarah; Koop, Christina; Graefen, Markus; Heinzer, Hans; Wittmer, Corinna; Sauter, Guido; Wilczak, Waldemar; Huland, Hartwig; Simon, Ronald; Schlomm, Thorsten; Steurer, Stefan; Krech, Till // Carcinogenesis;Nov2015, Vol. 36 Issue 11, p1333 

    Enhancer of zeste homolog 2 (EZH2) plays an important role in tumor development and progression by interacting with histone and nonhistone proteins. In the current study, we analyzed prevalence and prognostic impact of EZH2 in prostate cancer. EZH2 expression was analyzed by immunohistochemistry...

  • MGr1-Ag/37LRP promotes growth and proliferation of gastric cancer in vitro and in vivo. Liu, L; Sun, L; Wu, K; Shi, Y; Wang, Y; Zhang, N; Zhang, H // Cancer Gene Therapy;Sep2014, Vol. 21 Issue 9, p355 

    Gastric carcinoma (GC) is an aggressive cancer with a poor prognosis. We previously reported that MGr1-Ag was involved in multidrug resistance and anti-apoptosis in GC. However, the exact function of MGr1-Ag in GC proliferation is not clear. In this study, we found that MGr1-Ag was highly...

  • Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival. Rezano, Andri; Kuwahara, Kazuhiko; Yamamoto-Ibusuki, Mutsuko; Kitabatake, Masahiro; Moolthiya, Penpak; Phimsen, Suchada; Suda, Taiji; Tone, Shigenobu; Yamamoto, Yutaka; Iwase, Hirotaka; Sakaguchi, Nobuo // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background Genetic BRCA2 insufficiency is associated with breast cancer development; however, in sporadic breast cancer cases, high BRCA2 expression is paradoxically correlated with poor prognosis. Because DSS1, a mammalian component of the transcription/RNA export complex, is known to stabilize...

  • Researchers Deconstruct Metastasis. Hampton, Tracy // JAMA: Journal of the American Medical Association;12/5/2007, Vol. 298 Issue 21, p2471 

    This article reports on papers presented at the Oncogenes and Human Cancer: The Next 25 Years conference. Cancer metastasis causes 90 percent of all cancer deaths and offers a poor prognosis for cancer patients but those attending the conference heard some good news on research efforts that are...

  • Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas. Vincent-Salomon, Anne; Benhamo, Vanessa; Gravier, Eléonore; Rigaill, Guillem; Gruel, Nadège; Robin, Stéphane; de Rycke, Yann; Mariani, Odette; Pierron, Gaëlle; Gentien, David; Reyal, Fabien; Cottu, Paul; Fourquet, Alain; Rouzier, Roman; Sastre-Garau, Xavier; Delattre, Olivier // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background:The accurate prognosis definition to tailor treatment for early luminal invasive breast carcinoma patients remains challenging. Materials and Methods:Two hundred fourteen early luminal breast carcinomas were genotyped with single nucleotide polymorphisms (SNPs) array to determine...

  • Prognostic value of proliferation in invasive breast cancer: a review. van Diest, P. J.; van der Wall, E.; Baak, J. P. A. // Journal of Clinical Pathology;Jul2004, Vol. 57 Issue 7, p675 

    Breast cancer is the leading cause of death among solid tumours in women, and its incidence is increasing in the West. Adjuvant chemotherapy and hormonal treatment improve survival but have potentially serious side effects, and are costly. Because adjuvant treatment should be given to high risk...

  • NDRG1 expression is related to the progression and prognosis of gastric cancer patients through modulating proliferation, invasion and cell cycle of gastric cancer cells. Chang, Xiaojing; Xu, Xiaoyang; Ma, Jinguo; Xue, Xiaoying; Li, Zhenhua; Deng, Peng; Zhang, Shuanglong; Zhi, Yu; Chen, Jing; Dai, Dongqiu // Molecular Biology Reports;Sep2014, Vol. 41 Issue 9, p6215 

    N-myc downstream-regulated gene 1 (NDRG1) has been proposed as a tumor suppressor gene in many different types of tumors, but its potential function and corresponding mechanism are not yet fully elucidated. This study aims to detect the possible function of NDRG1 in gastric cancer progression....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics